Sugi Predict

Sugi Predict / Compounds / SCHEMBL767109

SCHEMBL767109

SCHEMBL767109

Clc1c(Br)ccc2[nH]ncc12

nearest known ligand 0.55

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ NOS1 P29475 9/20 0.55
▸ AXL P30530 2/20 0.55
▸ METAP2 P50579 4/20 0.41
▸ CSNK2A1 P68400 1/20 0.41
▸ IDO1 P14902 3/20 0.40
▸ TDO2 P48775 2/20 0.40
▸ DYRK1A Q13627 2/20 0.37
▸ CCNA2 P20248 1/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ CCNA1 P78396 1/20 0.36
▸ ESR1 P03372 2/20 0.35
▸ ESR2 Q92731 2/20 0.35
▸ TRPA1 O75762 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31050025 0.80 NOS1 (0.50) NOS1AXLMETAP2CSNK2A1IDO1
SCHEMBL25396754 0.80 NOS1 (0.50) NOS1AXLMETAP2CSNK2A1IDO1
SCHEMBL18038216 0.76 NOS1 (0.50) NOS1AXLMETAP2IDO1TDO2
SCHEMBL10172282 0.76 NOS1 (0.50) NOS1AXLMETAP2CSNK2A1IDO1
SCHEMBL2005907 0.76 NOS1 (0.55) NOS1AXLMETAP2CSNK2A1IDO1
SCHEMBL12821601 0.76 NOS1 (0.55) NOS1AXLMETAP2CSNK2A1IDO1
SCHEMBL5412653 0.76 NOS1 (0.50) NOS1AXLMETAP2IDO1DYRK1A
SCHEMBL20439372 0.76 NOS1 (0.55) NOS1AXLMETAP2CSNK2A1IDO1
SCHEMBL767506 0.76 NOS1 (0.55) NOS1AXLMETAP2CSNK2A1IDO1
SCHEMBL29474180 0.76 NOS1 (0.55) NOS1AXLMETAP2CSNK2A1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617783-B2 Heterocyclic GLP-1R agonists BIOMEA FUSION, INC. (US) 2026-05-05 — — US disclosed
US-20260109699-A1 AZOLE DERIVATIVES AS SHP2 INHIBITORS IRBM S.P.A. (IT) 2026-04-23 — — US disclosed
US-20260102394-A1 PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2026-04-16 — — US disclosed
EP-4713096-A1 CDK INHIBITOR COMPOUNDS Aleksia Therapeutics, Inc. (US) 2026-03-25 — — EP disclosed
US-12458640-B2 Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-11-04 — — US disclosed
US-20250304572-A1 HETEROCYCLIC GLP-1R AGONISTS BIOMEA FUSION, INC. 2025-10-02 — — US disclosed
US-20250304537-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME REPARE THERAPEUTICS INC. (CA) 2025-10-02 — — US disclosed
EP-4615847-A1 SMALL MOLECULE INHIBITORS OF KRAS PROTEINS Merck Sharp & Dohme LLC (US) 2025-09-17 — — EP disclosed
EP-4594324-A1 AZOLE DERIVATIVES AS SHP2 INHIBITORS IRBM S.P.A. (IT) 2025-08-06 — — EP disclosed
WO-2025136346-A1 INDAZOLE CONTAINING COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2025-06-26 — — WO disclosed
US-8299112-B2 Estrogen receptor modulators and uses thereof ARAGON PHARMACEUTICALS, INC. (US) 2012-10-30 — — US disclosed
US-8299112-B2 Estrogen receptor modulators and uses thereof ARAGON PHARMACEUTICALS, INC. (US) 2012-10-30 — — US disclosed
US-8299112-B2 Estrogen receptor modulators and uses thereof ARAGON PHARMACEUTICALS, INC. (US) 2012-10-30 — — US disclosed
WO-2012037411-A9 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ARAGON PHARMACEUTICALS, INC. (US) 2012-05-18 — — WO disclosed
WO-2012037410-A9 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ARAGON PHARMACEUTICALS, INC. (US) 2012-05-10 — — WO disclosed
WO-2012037410-A2 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ARAGON PHARMACEUTICALS, INC. (US) 2012-03-22 — — WO disclosed
WO-2012037411-A2 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ARAGON PHARMACEUTICALS, INC. (US) 2012-03-22 — — WO disclosed
US-20120071535-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ARAGON PHARMACEUTICALS, INC. (US) 2012-03-22 — — US disclosed
US-20120071535-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ARAGON PHARMACEUTICALS, INC. (US) 2012-03-22 — — US disclosed
US-20120071535-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ARAGON PHARMACEUTICALS, INC. (US) 2012-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304572-A1 HETEROCYCLIC GLP-1R AGONISTS GLP1R, GPR119, GIPR NOS1 2874/4885AXL 2612/4885METAP2 2099/4885
US-20250304537-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME CSNK1A1, CSNK1G1, CSNK2A1 NOS1 4253/4885AXL 1172/4885METAP2 956/4885
US-12617783-B2 Heterocyclic GLP-1R agonists GLP1R, GIPR, GPR119 NOS1 1583/4885AXL 805/4885METAP2 3437/4885
US-12458640-B2 Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors PTPN5, PTPRZ1, PTPN1 NOS1 3679/4885AXL 306/4885METAP2 2353/4885
US-20260109699-A1 AZOLE DERIVATIVES AS SHP2 INHIBITORS PTPN1, PTPN5, PTPN3 NOS1 3526/4885AXL 500/4885METAP2 4264/4885
US-20260102394-A1 PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS PTPN5, PTPN1, PTPN3 NOS1 3183/4885AXL 203/4885METAP2 2218/4885
US-20120071535-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ESR2, ESRRG, GPER1 NOS1 3625/4885AXL 1416/4885METAP2 1741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.